Optimum duration of regimens for Helicobacter pylori eradication (Q24201841)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

meta-analysis

0 references

title

Optimum duration of regimens for Helicobacter pylori eradication (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

Helicobacter pylori infectious disease

3 March 2020

main subject

Helicobacter pylori

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Alexander C. Ford

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Javier P Gisbert

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Xavier Calvet

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Paul Moayyedi

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Khurram J Khan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

David Forman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Grigorios I Leontiadis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Frances Tse

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Carlo Fallone

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Lori Fischbach

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Giuseppina Oderda

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Franco Bazzoli

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

11 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

3 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

CD008337

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Rank order of success favors longer duration of imidazole-based therapy for Helicobacter pylori in duodenal ulcer disease: a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Low dose of clarithromycin in triple therapy for the eradication of Helicobacter pylori: one or two weeks?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Levofloxacin based regimens for the eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Use of bovine lactoferrin for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized contr

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Seven-day therapy for Helicobacter pylori in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Use of lactoferrin for Helicobacter pylori eradication. Preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

How can the current strategies for Helicobacter pylori eradication therapy be improved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Efficacy and safety of faropenem in eradication therapy of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Meta-analysis, Simpson's paradox, and the number needed to treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Could increasing the duration of triple therapy be a clinically useful strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Simpson's paradox and calculation of number needed to treat from meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Individual patient data meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Determinants of non-compliance with short term antibiotic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

The number needed to treat: a clinically useful measure of treatment effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

'Rescue' therapies for the management of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Meta-analysis: principles and procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Asia-Pacific consensus guidelines on gastric cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Epidemiology of Helicobacter pylori infection and public health implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta‐analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Ranitidine bismuth citrate therapy regimens for treatment of Helicobacter pylori infection: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists--their efficacy with antibiotics in Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Evolution of Helicobacter pylori therapy from a meta-analytical perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Bias in clinical intervention research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Room for improvement? A survey of the methods used in systematic reviews of adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

New concepts of resistance in the treatment of Helicobacter pylori infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Helicobacter pylori treatment in the era of increasing antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Canadian Helicobacter pylori consensus conference. Canadian Association of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori--an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Nodal relapse after Helicobacter pylori eradication in a patient with primary localized gastric mucosa-associated lymphoid tissue lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Management of patients with ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Clarithromycin for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Helicobacter pylori: clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Ranitidine bismuth citrate: a novel anti-ulcer agent with different physico-chemical characteristics and improved biological activity to a bismuth citrate-ranitidine admixture

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Meta-analysis: Can we mix apples and oranges?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

The health economics of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Pooling data for number needed to treat: no problems for apples

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Update on Therapeutic Options for Helicobacter pylori-related Diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

"No language restrictions" in database searches: what does this really mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

A meta-analysis of the success rate of Helicobacter pylori therapy in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Overstating the evidence: double counting in meta-analysis and related problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Meta-analysis of individual patient data from randomized trials: a review of methods used in practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

High-dose versus standard-dose PPI in triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Systematic review: the global incidence and prevalence of peptic ulcer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Guidelines for the management of dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

American gastroenterological association technical review on the evaluation of dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Treating H. pylori shorter than one week--a real future perspective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

H. pylori treatment: new wine in old bottles?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Helicobacter pylori diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Response to Glanville et al.: How to identify randomized controlled trials in MEDLINE: ten years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Misleading Statistics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Helicobacter pylori infection and gender: a meta-analysis of population-based prevalence surveys

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery--fourteen days superior to seven days?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Treatment of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Comparison of 1- and 2-week pantoprazole-based triple therapies in clarithromycin-sensitive and resistant cases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Was It Really an “Ugly” Meta-Analysis?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Helicobacter pylori cagA and vacA Genotypes as Predictors of Progression of Gastric Preneoplastic Lesions: A Long-Term Follow-Up in a High-Risk Area in Spain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Small intestinal bacterial overgrowth and Helicobacter pylori: can they be cause of thrombocytopenia in patients with chronic liver disease?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Levofloxacin-based three-antibiotic regimen for H. pylori eradication

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Long-Term Follow-Up of 1,000 Patients Cured of Helicobacter pylori Infection Following an Episode of Peptic Ulcer Bleeding

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Triple vs. quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Effectiveness of omeprazole-amoxicillin-clarithromycin (OAC) therapy for Helicobacter pylori infection in a Japanese population

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of Helicobacter pylori: a report from India

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Resistance rates of metronidazole and other antibacterials in Helicobacter pylori from previously untreated patients in Norway

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Rapid eradication of Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse: comparison of 1 week and 2 week regimens and recrudescence rates over 12 months

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

One-week versus two-week furazolidone-based quadruple therapy as the first-line treatment for Helicobacter pylori infection in Iran

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

2-Week Triple Therapy for Helicobacter pylori Infection is Better Than 1-Week in Clinical Practice: a Large Prospective Single-Center Randomized Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

¿Siete o diez días? Estudio de coste-efectividad sobre la duración del tratamiento de la infección por H. pylori en atención primaria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

Comparison of one week and two weeks of triple therapy for the eradication of Helicobacter pylori in a Sri Lankan population: a randomised, controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008337.PUB2

7 January 2021

10.1002/14651858.CD008337.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

3697074

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338763%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

3697074

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

3697074